Vir Biotechnology Inc VIR shares are tumbling after the company released data from the Phase 2 PENINSULA evaluating VIR-2482 to prevent symptomatic influenza A illness.
The trial did not meet primary or secondary efficacy endpoints.
In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed.
Participants who received the highest dose showed an approximately 57% reduction in symptomatic influenza A illness, one of two secondary endpoints.
VIR-2482 was generally well tolerated, and no safety signals were identified.
The dose-ranging, proof-of-concept trial enrolled approximately 3,000 participants without risk factors for serious complications from an influenza infection who did not receive an influenza vaccination for the flu season.
Price Action: VIR shares are down 41.6% at $13.68 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
